empagliflozin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases cardiovascular mortality
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“The results indicated that Empagliflozin group exhibited a lower cardiovascular disease mortality rate versus Ctrl group (OR = 0.89, 95% CI: 0.82 to 0.97, Z = 2.73, P =.006), while neglectable difference existed in the all-cause mortality rate versus Ctrl group (OR = 0.92, 95% CI: 0.84 to 1.01, Z = 1.72, P =.09).”
Quoted verbatim from Meta-analysis of the efficacy and impact on cardiac function of sodium-glucose cotransporter 2 inhibitor Empagliflozin in heart failure patients.. - Study
- meta-analysis
- Dose
- 10 mg
- Population
- Patients with heart failure of any type; 15 pooled RCTs, empagliflozin 10 mg versus placebo (control group)
Effect 0.89 odds ratio, 95% CI 0.82 to 0.97
Meta-analysis of the efficacy and impact on cardiac function of sodium-glucose cotransporter 2 inhibitor Empagliflozin in heart failure patients.2024PMID:39533603Permalink
Keep reading
- Everything the graph holds on empagliflozin
- Every compound studied against Cardiovascular mortality
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45EDZG50EME9B1V9W46KXB6